Pharmacokinetic analysis of ductal carcinoma in situ of the breast using dynamic MR mammography

The purpose of this study was to assess the relationship between functional parameters derived from dynamic MR imaging and the histological findings of breast ductal carcinoma in situ (DCIS) and DCIS with invasive foci, and to evaluate whether these parameters might predict DCIS patient outcome. Two parameters, amplitude A and k21, were determined from multicompartmental pharmacokinetic analyses of dynamic MR mammography in 39 patients with needle biopsy-proven primary DCIS. After surgery, the histological tumor characteristics, including microvessel density (MVD) (anti-CD-34), vascular permeability (anti-VEGF antigen) and histological grade, were evaluated. Histology revealed 27 pure DCIS and 12 DCIS with invasive foci. In pure DCIS, positive correlations between MVD and amplitude A (r=0.56, P<0.0025) and between MVD and k21 (r=0.43, P=0.02) were found. As for histological grade, the differences in both functional parameters of grade 1 versus grade 2 and grade 1 versus grades 2 and 3 combined were significant (P<0.05). No significance was found in the analysis of DCIS with invasive foci. Our results indicated that functional MRI-based parameters might possess the potential to predict the outcome of patients with DCIS. Further study will be needed with larger series over longer periods.

[1]  Scott Fields,et al.  Mapping pathophysiological features of breast tumors by MRI at high spatial resolution , 1997, Nature Medicine.

[2]  F Pozza,et al.  Tumor angiogenesis: a new significant and independent prognostic indicator in early-stage breast carcinoma. , 1992, Journal of the National Cancer Institute.

[3]  R. Gilles,et al.  Ductal carcinoma in situ: MR imaging-histopathologic correlation. , 1995, Radiology.

[4]  D M Shames,et al.  MR imaging characterization of microvessels in experimental breast tumors by using a particulate contrast agent with histopathologic correlation. , 2001, Radiology.

[5]  G Brix,et al.  Multicompartment analysis of gadolinium chelate kinetics: Blood‐tissue exchange in mammary tumors as monitored by dynamic MR imaging , 1999, Journal of magnetic resonance imaging : JMRI.

[6]  W T Yuh,et al.  MR microcirculation assessment in cervical cancer: Correlations with histomorphological tumor markers and clinical outcome , 1999, Journal of magnetic resonance imaging : JMRI.

[7]  D. Gomez,et al.  Expression of vascular endothelial growth factor, its receptor, and other angiogenic factors in human breast cancer. , 1996, Cancer research.

[8]  S. Heywang-Köbrunner,et al.  In situ and minimally invasive breast cancer: morphologic and kinetic features on contrast-enhanced MR imaging , 2000, Magma: Magnetic Resonance Materials in Physics, Biology, and Medicine.

[9]  M. Neeman,et al.  Stabilization of vascular endothelial growth factor mRNA by hypoxia and hypoglycemia and coregulation with other ischemia-induced genes , 1995, Molecular and cellular biology.

[10]  M. Toi,et al.  Association of Vascular Endothelial Growth Factor Expression with Tumor Angiogenesis and with Early Relapse in Primary Breast Cancer , 1994, Japanese journal of cancer research : Gann.

[11]  L D Buadu,et al.  Breast lesions: correlation of contrast medium enhancement patterns on MR images with histopathologic findings and tumor angiogenesis. , 1996, Radiology.

[12]  W. Reddick,et al.  Dynamic magnetic resonance imaging of regional contrast access as an additional prognostic factor in pediatric osteosarcoma , 2001, Cancer.

[13]  A. D. De Schepper,et al.  Preoperative breast MRI in patients with invasive lobular breast cancer , 2004, European Radiology.

[14]  R. Chandra,et al.  MR imaging of microvasculature , 2000, Magnetic resonance in medicine.

[15]  W. Kaiser,et al.  High grade and non-high grade ductal carcinoma in situ on dynamic MR mammography: characteristic findings for signal increase and morphological pattern of enhancement. , 2003, The British journal of radiology.

[16]  S G Orel,et al.  Differentiating benign from malignant enhancing lesions identified at MR imaging of the breast: are time-signal intensity curves an accurate predictor? , 1999, Radiology.

[17]  W. Dupont,et al.  Intraductal carcinoma of the breast: Follow‐up after biopsy only , 1982, Cancer.

[18]  A. Santinelli,et al.  Microvessel quantitation in intraductal and early invasive breast carcinomas. , 2000, Analytical and quantitative cytology and histology.

[19]  S. Heffelfinger,et al.  Vascularity of proliferative breast disease and carcinoma in situ correlates with histological features. , 1996, Clinical cancer research : an official journal of the American Association for Cancer Research.

[20]  Tibor Tot,et al.  Invasive breast cancer: correlation of dynamic MR features with prognostic factors , 2003, European Radiology.

[21]  M. Toi,et al.  Quantitative analysis of vascular endothelial growth factor in primary breast cancer , 1996, Cancer.

[22]  J. Folkman,et al.  Tumor angiogenesis and metastasis--correlation in invasive breast carcinoma. , 1991, The New England journal of medicine.

[23]  M. Silverstein,et al.  A prognostic index for ductal carcinoma in situ of the breast , 1996, Cancer.

[24]  Anthony J. Guidi,et al.  Microvessel density and distribution in ductal carcinoma in situ of the breast. , 1994, Journal of the National Cancer Institute.

[25]  H. Karakas,et al.  Evaluation of Tumor Angiogenesis with Contrast‐Enhanced Dynamic Magnetic Resonance Mammography , 2003, The breast journal.

[26]  D B Kopans,et al.  Dynamic echo-planar imaging of the breast: experience in diagnosing breast carcinoma and correlation with tumor angiogenesis. , 1997, Radiology.

[27]  M. Neeman,et al.  Induction of vascular endothelial growth factor expression by hypoxia and by glucose deficiency in multicell spheroids: implications for tumor angiogenesis. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[28]  G Brix,et al.  Angiogenesis of uterine cervical carcinoma: characterization by pharmacokinetic magnetic resonance parameters and histological microvessel density with correlation to lymphatic involvement. , 1997, Cancer research.

[29]  A Horsman,et al.  Dynamic MR imaging of invasive breast cancer: correlation with tumour grade and other histological factors. , 1997, The British journal of radiology.

[30]  L R Schad,et al.  Pharmacokinetic parameters in CNS Gd-DTPA enhanced MR imaging. , 1991, Journal of computer assisted tomography.

[31]  M. Lagios.  Heterogeneity of duct carcinoma in situ (DCIS): relationship of grade and subtype analysis to local recurrence and risk of invasive transformation. , 1995, Cancer letters.

[32]  U. Bick,et al.  Differentiation between benign and malignant findings on MR-mammography: usefulness of morphological criteria , 2001, European Radiology.

[33]  S. Heffelfinger,et al.  Angiogenic growth factors in preinvasive breast disease. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[34]  H. Gallager,et al.  Intraductal carcinoma of the breast. A comparative study. , 1975, American journal of surgery.

[35]  M. Schnall,et al.  MR imaging of ductal carcinoma in situ. , 1997, Radiology.

[36]  M V Knopp,et al.  Angiogenic activity of cervical carcinoma: assessment by functional magnetic resonance imaging-based parameters and a histomorphological approach in correlation with disease outcome. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

[37]  G Brix,et al.  Pathophysiologic basis of contrast enhancement in breast tumors , 1999, Journal of magnetic resonance imaging : JMRI.

[38]  P J Drew,et al.  Dynamic MR imaging of the breast combined with analysis of contrast agent kinetics in the differentiation of primary breast tumours. , 1997, Clinical radiology.

[39]  B. Daniel,et al.  Potential role of magnetic resonance imaging and other modalities in ductal carcinoma in situ detection. , 2001, Magnetic resonance imaging clinics of North America.

[40]  A. Lee,et al.  Microvessel quantitation and prognosis in invasive breast carcinoma. , 1992, Human pathology.

[41]  P Aspelin,et al.  Contrast-enhanced MR imaging as a prognostic indicator of breast cancer , 1998, Acta radiologica.

[42]  M. Silverstein,et al.  Intraductal carcinoma of the breast (208 cases): Clinical factors influencing treatment choice , 1990, Cancer.

[43]  J. Weyler,et al.  Enhancing area surrounding breast carcinoma on MR mammography: comparison with pathological examination , 2004, European Radiology.

[44]  A. Harris,et al.  Angiogenesis, assessed by platelet/endothelial cell adhesion molecule antibodies, as indicator of node metastases and survival in breast cancer , 1992, The Lancet.

[45]  Anthony J. Guidi,et al.  Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in breast cancer. , 1995, Human pathology.

[46]  Anthony J. Guidi,et al.  Vascular permeability factor (Vascular endothelial growth factor) expression and angiogenesis in patients with ductal carcinoma in situ of the breast , 1997, Cancer.

[47]  G. Schwartz,et al.  Consensus Conference on the Classification of Ductal Carcinoma of the Breast, April 22–25, 1999 , 2000, The breast journal.